|
Market Closed -
Nasdaq
16:00:00 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 1.040 USD | -4.59% |
|
-11.86% | -24.09% |
| 11-06 | Allogene Therapeutics, Inc., Q3 2026 Earnings Call, Nov 05, 2026 | |
| 11-05 | Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2026 | CI |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 359.3 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 16.7% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 13.16 | 209.1 | 28.21 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | -96.21% | 1,489.52% | -86.51% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -1.73x | -1.62x | -1.86x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 0.9x | 1.8x | 0.81x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.1x | -0.25x | 0.1x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 77.8x | 30.8x | 4.27x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 2.85x | 17.9x | 0.34x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -0.07x | -0.87x | -0.1x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -0.06x | -0.87x | -0.13x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -0.1x | -1.43x | -0.22x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -960% | -69.8% | -445% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.6022 | -0.642 | -0.5596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 4.62 | 11.68 | 84.13 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -200.2 | -239.7 | -269.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -210.5 | -240.3 | -218.3 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -185.3 | -219.8 | -212.4 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -346.2 | -150.2 | -331.1 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 1.040 | 1.040 | 1.040 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,491 | - | - |
| Announcement Date | 2/23/22 | 2/28/23 | 3/14/24 | 3/13/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.73x | 42.59x | -0.81x | -.--% | 359M | |
| 17.43x | 6.6x | 12.65x | 1.71% | 65.94B | |
| 38.45x | 6.85x | 20.42x | 0.85% | 56.53B | |
| 30.07x | 8.27x | 26.77x | 0.06% | 56.88B | |
| 49.29x | 6.27x | 34.36x | -.--% | 46.49B | |
| 35.48x | 3.35x | 14.48x | -.--% | 44.8B | |
| -22.45x | 63.4x | -21.48x | -.--% | 41.59B | |
| 35.89x | 8.84x | 23.03x | 0.37% | 35.35B | |
| 37.6x | 8.06x | 26.12x | -.--% | 33.29B | |
| 28.81x | 6.09x | 15.79x | -.--% | 24.92B | |
| Average | 24.88x | 16.03x | 15.13x | 0.3% | 40.61B | |
| Weighted average by Cap. | 27.62x | 12.60x | 17.09x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
